Exogenus
Therapeutics
Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Latest news
Exogenus Therapeutics joins the massivEVs workshop to share insights about Exo-101’s production process and composition
Our team member Carla Pereira will be attending the massivEVs workshop, organized by ISEV, with a poster titled “Manufacturing and characterization of extracellular vesicles from umbilical...
Exogenus Therapeutics receives 1st Place in the category of BioTech at the 2021 Go Global Awards
Exogenus Therapeutics was announced as 1st Place in the category of BioTech on the 14th October 2021, at the International Trade Council's Annual Go Global Awards Ceremony. Founded in...
Exogenus Therapeutics strengthens IP portfolio with patent granted in Japan
Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in Japan. The patent...